| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 13 | 2024 | 51 | 2.200 |
Why?
|
| Veterans | 13 | 2026 | 210 | 1.600 |
Why?
|
| Infant Nutritional Physiological Phenomena | 6 | 2024 | 36 | 1.300 |
Why?
|
| Primary Health Care | 12 | 2026 | 380 | 1.200 |
Why?
|
| Infant, Very Low Birth Weight | 7 | 2024 | 50 | 1.160 |
Why?
|
| Iodine | 5 | 2025 | 11 | 1.050 |
Why?
|
| United States Department of Veterans Affairs | 12 | 2026 | 42 | 0.920 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 41 | 0.840 |
Why?
|
| Testosterone | 9 | 2013 | 211 | 0.790 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2023 | 760 | 0.760 |
Why?
|
| Hemophilia B | 1 | 2020 | 2 | 0.680 |
Why?
|
| Factor IX | 1 | 2020 | 3 | 0.670 |
Why?
|
| Hypothyroidism | 3 | 2025 | 26 | 0.650 |
Why?
|
| Male | 62 | 2025 | 23409 | 0.630 |
Why?
|
| Hyperthyroidism | 3 | 2025 | 8 | 0.630 |
Why?
|
| Heart Failure | 5 | 2023 | 302 | 0.630 |
Why?
|
| Middle Aged | 46 | 2026 | 12222 | 0.630 |
Why?
|
| Atherosclerosis | 3 | 2013 | 169 | 0.620 |
Why?
|
| Infant, Premature | 6 | 2024 | 134 | 0.620 |
Why?
|
| Contrast Media | 3 | 2025 | 103 | 0.600 |
Why?
|
| Telemedicine | 5 | 2025 | 234 | 0.600 |
Why?
|
| Female | 56 | 2026 | 24698 | 0.600 |
Why?
|
| Humans | 83 | 2026 | 43102 | 0.600 |
Why?
|
| Aged | 35 | 2026 | 8214 | 0.570 |
Why?
|
| Enterocolitis, Necrotizing | 4 | 2021 | 24 | 0.530 |
Why?
|
| United States | 28 | 2026 | 5205 | 0.510 |
Why?
|
| Mental Health Services | 3 | 2025 | 141 | 0.490 |
Why?
|
| Infant Formula | 4 | 2018 | 17 | 0.490 |
Why?
|
| Prediabetic State | 2 | 2014 | 69 | 0.470 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2025 | 40 | 0.450 |
Why?
|
| Parenteral Nutrition | 3 | 2024 | 15 | 0.450 |
Why?
|
| Thyroid Diseases | 2 | 2025 | 6 | 0.430 |
Why?
|
| Infant, Newborn | 10 | 2024 | 972 | 0.420 |
Why?
|
| Adult | 29 | 2026 | 13872 | 0.410 |
Why?
|
| Cholesterol | 2 | 2013 | 232 | 0.400 |
Why?
|
| Hyperlipidemias | 2 | 2013 | 48 | 0.400 |
Why?
|
| Androgens | 1 | 2013 | 106 | 0.390 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 25 | 0.390 |
Why?
|
| Aging | 4 | 2013 | 783 | 0.370 |
Why?
|
| Insurance, Health | 1 | 2013 | 145 | 0.360 |
Why?
|
| Quality of Health Care | 4 | 2025 | 161 | 0.360 |
Why?
|
| Vitamin K | 3 | 2016 | 9 | 0.350 |
Why?
|
| Truth Disclosure | 1 | 2011 | 26 | 0.350 |
Why?
|
| Stereotyping | 1 | 2011 | 45 | 0.340 |
Why?
|
| Weight Gain | 4 | 2024 | 139 | 0.340 |
Why?
|
| Health Care Surveys | 2 | 2020 | 152 | 0.340 |
Why?
|
| Ischemic Attack, Transient | 2 | 2021 | 22 | 0.340 |
Why?
|
| Nicotine | 4 | 2024 | 302 | 0.310 |
Why?
|
| Electronic Health Records | 2 | 2024 | 108 | 0.300 |
Why?
|
| Mental Disorders | 2 | 2025 | 392 | 0.300 |
Why?
|
| Oligosaccharides | 3 | 2024 | 29 | 0.300 |
Why?
|
| Hormone Replacement Therapy | 3 | 2025 | 49 | 0.300 |
Why?
|
| Retrospective Studies | 12 | 2025 | 2544 | 0.300 |
Why?
|
| Social Support | 2 | 2012 | 445 | 0.290 |
Why?
|
| Dietary Fats | 3 | 2024 | 117 | 0.290 |
Why?
|
| Lower Extremity | 2 | 2019 | 38 | 0.290 |
Why?
|
| Double-Blind Method | 9 | 2023 | 317 | 0.290 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2019 | 77 | 0.280 |
Why?
|
| Hypertension | 3 | 2021 | 835 | 0.280 |
Why?
|
| Smoking Cessation | 3 | 2023 | 590 | 0.280 |
Why?
|
| Lipids | 3 | 2006 | 256 | 0.280 |
Why?
|
| Depression | 3 | 2025 | 863 | 0.270 |
Why?
|
| Blood Coagulation Factors | 3 | 2016 | 7 | 0.270 |
Why?
|
| Risk Reduction Behavior | 2 | 2026 | 138 | 0.260 |
Why?
|
| Health Services | 2 | 2009 | 61 | 0.250 |
Why?
|
| Health Promotion | 3 | 2026 | 704 | 0.250 |
Why?
|
| Food, Fortified | 3 | 2016 | 11 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 497 | 0.250 |
Why?
|
| Medication Adherence | 2 | 2021 | 182 | 0.240 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 2853 | 0.240 |
Why?
|
| Disease Management | 3 | 2019 | 70 | 0.240 |
Why?
|
| Food Analysis | 1 | 2006 | 34 | 0.240 |
Why?
|
| Blood Viscosity | 3 | 2021 | 9 | 0.240 |
Why?
|
| Nutritive Value | 1 | 2006 | 37 | 0.240 |
Why?
|
| Muscle, Skeletal | 6 | 2006 | 316 | 0.230 |
Why?
|
| Plasma | 2 | 2016 | 38 | 0.230 |
Why?
|
| Prospective Studies | 10 | 2025 | 1600 | 0.230 |
Why?
|
| Breast Feeding | 2 | 2018 | 126 | 0.230 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2025 | 3 | 0.230 |
Why?
|
| Echocardiography | 2 | 2024 | 167 | 0.230 |
Why?
|
| Patient-Centered Care | 2 | 2024 | 75 | 0.230 |
Why?
|
| Adolescent | 11 | 2023 | 6081 | 0.230 |
Why?
|
| Parkinson Disease | 2 | 2019 | 210 | 0.230 |
Why?
|
| Triiodothyronine | 1 | 2025 | 36 | 0.230 |
Why?
|
| Hospitals, Veterans | 3 | 2020 | 15 | 0.230 |
Why?
|
| Patient Participation | 1 | 2026 | 94 | 0.220 |
Why?
|
| Niacinamide | 1 | 2024 | 16 | 0.210 |
Why?
|
| Bifidobacterium | 1 | 2024 | 4 | 0.210 |
Why?
|
| Quality of Life | 4 | 2023 | 616 | 0.210 |
Why?
|
| Pyridinium Compounds | 1 | 2024 | 29 | 0.210 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 706 | 0.210 |
Why?
|
| Birth Weight | 5 | 2018 | 95 | 0.210 |
Why?
|
| Burnout, Professional | 1 | 2024 | 31 | 0.210 |
Why?
|
| Atrial Flutter | 1 | 2023 | 7 | 0.210 |
Why?
|
| Dietary Proteins | 2 | 2017 | 35 | 0.210 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 3156 | 0.200 |
Why?
|
| Electrocardiography | 1 | 2024 | 185 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 1869 | 0.200 |
Why?
|
| Injections, Subcutaneous | 2 | 2020 | 36 | 0.190 |
Why?
|
| Heart | 1 | 2024 | 184 | 0.190 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2002 | 14 | 0.190 |
Why?
|
| Sampling Studies | 1 | 2002 | 64 | 0.190 |
Why?
|
| Microcirculation | 2 | 2019 | 40 | 0.190 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 122 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 16 | 0.180 |
Why?
|
| Fatty Liver | 2 | 2024 | 77 | 0.180 |
Why?
|
| Infant | 7 | 2023 | 1175 | 0.180 |
Why?
|
| Hypoglycemic Agents | 3 | 2023 | 184 | 0.170 |
Why?
|
| Risk Factors | 7 | 2025 | 3994 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2018 | 1124 | 0.170 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2020 | 1 | 0.170 |
Why?
|
| Partial Thromboplastin Time | 1 | 2020 | 9 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2024 | 122 | 0.160 |
Why?
|
| Urinary Incontinence | 1 | 2020 | 15 | 0.160 |
Why?
|
| HIV Infections | 3 | 2011 | 2586 | 0.160 |
Why?
|
| Hospitals, Community | 1 | 2020 | 13 | 0.160 |
Why?
|
| Drug Design | 2 | 2020 | 186 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 127 | 0.160 |
Why?
|
| Biological Availability | 1 | 2020 | 116 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2025 | 1759 | 0.160 |
Why?
|
| Dogs | 1 | 2020 | 204 | 0.160 |
Why?
|
| Tobacco Use Disorder | 1 | 2023 | 250 | 0.160 |
Why?
|
| Young Adult | 5 | 2018 | 5080 | 0.160 |
Why?
|
| Animals | 11 | 2024 | 16992 | 0.160 |
Why?
|
| Sulfonylurea Compounds | 1 | 2019 | 17 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 19 | 0.150 |
Why?
|
| Stroke | 2 | 2021 | 340 | 0.150 |
Why?
|
| Thyrotropin | 3 | 2023 | 24 | 0.150 |
Why?
|
| Dietary Supplements | 3 | 2016 | 213 | 0.150 |
Why?
|
| Respiratory Protective Devices | 1 | 2019 | 2 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 165 | 0.150 |
Why?
|
| Health Personnel | 2 | 2019 | 277 | 0.150 |
Why?
|
| Occupational Health | 1 | 2019 | 32 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2026 | 749 | 0.150 |
Why?
|
| Thromboembolism | 2 | 2016 | 20 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2020 | 233 | 0.140 |
Why?
|
| Infant, Extremely Low Birth Weight | 2 | 2016 | 31 | 0.140 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 26 | 0.140 |
Why?
|
| Metformin | 1 | 2019 | 75 | 0.140 |
Why?
|
| Equipment Design | 1 | 2019 | 145 | 0.140 |
Why?
|
| Cushing Syndrome | 1 | 2018 | 5 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 44 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 287 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2018 | 55 | 0.140 |
Why?
|
| California | 3 | 2012 | 548 | 0.140 |
Why?
|
| Workplace | 1 | 2019 | 92 | 0.140 |
Why?
|
| Lanthanum | 1 | 2017 | 2 | 0.130 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 4 | 0.130 |
Why?
|
| Aspirin | 1 | 2018 | 89 | 0.130 |
Why?
|
| Bone Diseases | 1 | 2017 | 18 | 0.130 |
Why?
|
| Benzamides | 1 | 2018 | 81 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2021 | 666 | 0.130 |
Why?
|
| Body Composition | 2 | 2011 | 159 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2019 | 1604 | 0.130 |
Why?
|
| Mass Screening | 3 | 2014 | 541 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 1063 | 0.130 |
Why?
|
| Models, Molecular | 1 | 2020 | 876 | 0.130 |
Why?
|
| Enteral Nutrition | 2 | 2018 | 17 | 0.130 |
Why?
|
| Research Design | 3 | 2025 | 385 | 0.130 |
Why?
|
| Gestational Age | 4 | 2021 | 200 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 539 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 50 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2024 | 1003 | 0.120 |
Why?
|
| Internet | 1 | 2018 | 236 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2016 | 62 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2017 | 131 | 0.120 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 78 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2015 | 36 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2016 | 55 | 0.120 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 53 | 0.120 |
Why?
|
| Receptors, Androgen | 3 | 2006 | 144 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 375 | 0.120 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 486 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 114 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 1067 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2016 | 187 | 0.110 |
Why?
|
| Thyroid Function Tests | 2 | 2025 | 7 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 49 | 0.110 |
Why?
|
| Mice | 7 | 2024 | 6644 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2015 | 96 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2006 | 587 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1596 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2015 | 69 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 44 | 0.110 |
Why?
|
| Length of Stay | 1 | 2016 | 229 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 246 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2015 | 61 | 0.110 |
Why?
|
| Triglycerides | 2 | 2021 | 147 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2013 | 490 | 0.100 |
Why?
|
| Morphine Dependence | 1 | 2013 | 23 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2014 | 90 | 0.100 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 52 | 0.100 |
Why?
|
| Insulin | 1 | 2015 | 258 | 0.100 |
Why?
|
| Feeding Behavior | 2 | 2016 | 469 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 234 | 0.100 |
Why?
|
| Time Factors | 5 | 2019 | 1857 | 0.100 |
Why?
|
| Morphine | 1 | 2013 | 69 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2013 | 91 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 638 | 0.090 |
Why?
|
| Community Health Services | 1 | 2014 | 206 | 0.090 |
Why?
|
| Eating | 1 | 2013 | 167 | 0.090 |
Why?
|
| Case Management | 1 | 2012 | 24 | 0.090 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2012 | 33 | 0.090 |
Why?
|
| Medicaid | 1 | 2013 | 143 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 92 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 252 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2021 | 48 | 0.080 |
Why?
|
| Asthma | 1 | 2015 | 416 | 0.080 |
Why?
|
| Vitamin D | 1 | 2012 | 196 | 0.080 |
Why?
|
| Dementia | 1 | 2012 | 160 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2020 | 549 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 73 | 0.080 |
Why?
|
| United States Indian Health Service | 1 | 2009 | 2 | 0.080 |
Why?
|
| Caregivers | 1 | 2012 | 197 | 0.080 |
Why?
|
| Lactose | 1 | 2009 | 16 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 53 | 0.070 |
Why?
|
| Blood Flow Velocity | 2 | 2019 | 87 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 2009 | 33 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 925 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 115 | 0.070 |
Why?
|
| Bisexuality | 1 | 2011 | 211 | 0.070 |
Why?
|
| Health Services Research | 1 | 2009 | 161 | 0.070 |
Why?
|
| Sexual Partners | 1 | 2011 | 326 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2011 | 457 | 0.070 |
Why?
|
| Cattle | 2 | 2021 | 498 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2008 | 142 | 0.070 |
Why?
|
| Body Weight | 3 | 2014 | 429 | 0.070 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 2 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 153 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 223 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2007 | 77 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 486 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 47 | 0.060 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 18 | 0.060 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2006 | 9 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 61 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 99 | 0.060 |
Why?
|
| International Normalized Ratio | 2 | 2016 | 9 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 195 | 0.060 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2006 | 70 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2006 | 122 | 0.060 |
Why?
|
| Thyroxine | 1 | 2025 | 22 | 0.060 |
Why?
|
| Brain | 1 | 2013 | 1472 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 263 | 0.060 |
Why?
|
| Forecasting | 2 | 2003 | 136 | 0.060 |
Why?
|
| Interviews as Topic | 3 | 2018 | 452 | 0.060 |
Why?
|
| Leuprolide | 1 | 2004 | 8 | 0.060 |
Why?
|
| Postmenopause | 1 | 2005 | 141 | 0.060 |
Why?
|
| Androstenedione | 1 | 2004 | 19 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2011 | 661 | 0.060 |
Why?
|
| Hypogonadism | 1 | 2004 | 23 | 0.060 |
Why?
|
| Pertussis Vaccine | 1 | 2004 | 2 | 0.050 |
Why?
|
| Bordetella pertussis | 1 | 2004 | 2 | 0.050 |
Why?
|
| Whooping Cough | 1 | 2004 | 4 | 0.050 |
Why?
|
| Databases, Factual | 3 | 2016 | 341 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2024 | 96 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 182 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2004 | 117 | 0.050 |
Why?
|
| Veillonella | 1 | 2023 | 1 | 0.050 |
Why?
|
| Energy Intake | 3 | 2011 | 164 | 0.050 |
Why?
|
| Linear Models | 2 | 2016 | 317 | 0.050 |
Why?
|
| Muscle Fatigue | 1 | 2003 | 9 | 0.050 |
Why?
|
| Leg | 1 | 2003 | 19 | 0.050 |
Why?
|
| Prebiotics | 1 | 2023 | 7 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 245 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2025 | 241 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2003 | 67 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2002 | 34 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 112 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2002 | 42 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 203 | 0.050 |
Why?
|
| Outpatients | 1 | 2002 | 37 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2003 | 55 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 236 | 0.050 |
Why?
|
| Lipoproteins, VLDL | 1 | 2021 | 4 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 229 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2015 | 389 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2021 | 70 | 0.040 |
Why?
|
| Exercise Test | 2 | 2016 | 74 | 0.040 |
Why?
|
| Physician Assistants | 1 | 2021 | 20 | 0.040 |
Why?
|
| Liver | 1 | 2024 | 511 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2021 | 39 | 0.040 |
Why?
|
| Nurse Practitioners | 1 | 2021 | 24 | 0.040 |
Why?
|
| Los Angeles | 2 | 2015 | 394 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 60 | 0.040 |
Why?
|
| Medical Records | 2 | 2015 | 48 | 0.040 |
Why?
|
| Gender Identity | 1 | 2021 | 117 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 512 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 37 | 0.040 |
Why?
|
| Sexual Behavior | 2 | 2021 | 638 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 167 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 60 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2015 | 1546 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1009 | 0.040 |
Why?
|
| Models, Biological | 1 | 2003 | 712 | 0.040 |
Why?
|
| Antimalarials | 1 | 2019 | 64 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2020 | 215 | 0.040 |
Why?
|
| Public Health | 1 | 2023 | 424 | 0.040 |
Why?
|
| Inhalation Exposure | 1 | 2019 | 44 | 0.040 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2018 | 19 | 0.040 |
Why?
|
| Physicians | 1 | 2021 | 188 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 55 | 0.040 |
Why?
|
| Smoking | 2 | 2022 | 1024 | 0.040 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2018 | 6 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2018 | 17 | 0.040 |
Why?
|
| Exercise | 2 | 2021 | 692 | 0.040 |
Why?
|
| New York City | 1 | 2019 | 288 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 432 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 278 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2019 | 91 | 0.030 |
Why?
|
| Milk | 1 | 2018 | 56 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2018 | 42 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 68 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1081 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2018 | 93 | 0.030 |
Why?
|
| Age Factors | 2 | 2015 | 1154 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 485 | 0.030 |
Why?
|
| Phosphorus | 1 | 2017 | 65 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 760 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 22 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 34 | 0.030 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2016 | 26 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 50 | 0.030 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2005 | 25 | 0.030 |
Why?
|
| Luteinizing Hormone | 2 | 2005 | 61 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2015 | 44 | 0.030 |
Why?
|
| Child | 2 | 2015 | 3443 | 0.030 |
Why?
|
| Child Development | 1 | 2016 | 99 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 826 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 68 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2015 | 122 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 737 | 0.030 |
Why?
|
| Drug Implants | 1 | 2013 | 20 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2013 | 34 | 0.030 |
Why?
|
| Reference Values | 2 | 2004 | 211 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 78 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1028 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 1234 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2012 | 35 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 75 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2012 | 36 | 0.020 |
Why?
|
| Austria | 1 | 2012 | 5 | 0.020 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2012 | 19 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2012 | 62 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 126 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2011 | 21 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2012 | 40 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2012 | 98 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 457 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 518 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 986 | 0.020 |
Why?
|
| Adiposity | 1 | 2011 | 157 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2003 | 587 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2012 | 574 | 0.020 |
Why?
|
| Milk Banks | 1 | 2009 | 3 | 0.020 |
Why?
|
| Medicare | 1 | 2012 | 332 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 2157 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 513 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 107 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2009 | 178 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 2 | 0.020 |
Why?
|
| Enema | 1 | 2006 | 10 | 0.020 |
Why?
|
| Myogenin | 1 | 2006 | 6 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2006 | 34 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 32 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 47 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2006 | 162 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2005 | 3 | 0.010 |
Why?
|
| Cell Count | 1 | 2006 | 145 | 0.010 |
Why?
|
| Receptors, Notch | 1 | 2006 | 38 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 210 | 0.010 |
Why?
|
| Hematocrit | 1 | 2005 | 26 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 41 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2005 | 39 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2006 | 141 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 177 | 0.010 |
Why?
|
| Gels | 1 | 2005 | 45 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 95 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 224 | 0.010 |
Why?
|
| Cell Division | 1 | 2006 | 311 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2005 | 37 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 64 | 0.010 |
Why?
|
| Health Status | 1 | 2008 | 442 | 0.010 |
Why?
|
| Prostate | 1 | 2005 | 155 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2004 | 65 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2004 | 86 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 611 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 934 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2004 | 144 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 388 | 0.010 |
Why?
|
| Thigh | 1 | 2003 | 12 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 695 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 52 | 0.010 |
Why?
|
| Hormones | 1 | 2003 | 55 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2003 | 76 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 81 | 0.010 |
Why?
|
| Organ Size | 1 | 2003 | 170 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 201 | 0.010 |
Why?
|
| Vaccination | 1 | 2004 | 355 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 437 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 638 | 0.010 |
Why?
|